Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Inoue K, et al. Among authors: hozumi y. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. doi: 10.1007/s10549-009-0498-7. Epub 2009 Aug 19. Breast Cancer Res Treat. 2010. PMID: 19690954 Clinical Trial.
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Aihara T, et al. Among authors: hozumi y. Breast Cancer Res Treat. 2010 Jun;121(2):379-87. doi: 10.1007/s10549-010-0888-x. Breast Cancer Res Treat. 2010. PMID: 20390343 Clinical Trial.
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T. Ohsumi S, et al. Among authors: hozumi y. Breast Cancer Res Treat. 2011 May;127(1):143-52. doi: 10.1007/s10549-011-1400-y. Epub 2011 Feb 24. Breast Cancer Res Treat. 2011. PMID: 21347648 Clinical Trial.
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y. Takei H, et al. Among authors: hozumi y. Breast Cancer Res Treat. 2012 May;133(1):227-36. doi: 10.1007/s10549-011-1943-y. Epub 2012 Jan 11. Breast Cancer Res Treat. 2012. PMID: 22234519 Clinical Trial.
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S. Takahashi S, et al. Among authors: hozumi y. Breast Cancer Res Treat. 2012 Jun;133(2):685-93. doi: 10.1007/s10549-012-1973-0. Epub 2012 Feb 4. Breast Cancer Res Treat. 2012. PMID: 22307266 Clinical Trial.
301 results